Table 3

Predicted daily health services use based on AQHI and pollutant levels

	AQHI=3		AQHI=6			AQHI=10
	(Low-health risk)		(Moderate-health risk)			(High-health risk)
	Predicted daily rate*	Expected number of visits†	Predicted daily rate*	Expected number of visits†	Per cent change‡	Predicted daily rate*	Expected number of visits†	Per cent change‡
Outpatient visits (sorted by highest to lowest expected no. of visits)
Hypertension	5.83	15 834	6.41	17 387	9.8	7.26	19 697	24.4
Diabetes	10.72	12 236	11.79	13 450	9.9	13.37	15 258	24.7
Non-lung cancers	5.53	7 437	6.38	8 581	15.4	7.72	10 384	39.6
Asthma	1.80	3 366	1.97	3 681	9.3	2.21	4 146	23.2
Stroke	5.21	2 648	5.24	2 666	0.7	5.29	2 691	1.6
COPD	2.41	1 660	2.82	1 940	16.9	3.47	2 388	43.9
Angina	1.51	1 544	1.70	1 741	12.8	2.00	2 045	32.4
Congestive heart failure	6.19	1 412	6.63	1 512	7.1	7.26	1 657	17.4
Ischaemic heart disease	5.18	1 138	5.43	1 193	4.9	5.79	1 271	11.8
Acute myocardial infarction	1.88	307	1.69	276	−10.3	1.46	238	−22.4
Lung Cancer	0.46	9	0.45	8	−3.8	0.42	8	−8.5
Hospitalisations (sorted by highest to lowest expected number of visits)
Non-lung cancers	0.19	250	0.20	270	7.9	0.22	299	19.3
Ischaemic heart disease	0.44	97	0.42	91	−6.1	0.38	84	−13.6
Diabetes	0.06	73	0.07	82	11.8	0.08	95	29.7
COPD	0.09	64	0.10	71	10.7	0.12	81	26.7
Acute myocardial infarction	0.40	65	0.36	59	−10.3	0.31	51	−22.4
Congestive heart failure	0.24	54	0.25	58	6.1	0.27	63	14.8
Stroke	0.09	47	0.09	44	−5.3	0.08	41	−11.8
Angina	0.03	32	0.03	34	7.9	0.04	38	19.4
Asthma	0.01	21	0.01	22	2.0	0.01	22	4.8
Lung Cancer	1.03	20	0.92	17	−11.0	0.79	15	−23.7
Hypertension	0.00	7	0.00	8	7.2	0.00	9	17.5

*Predicted daily average rates per 1000 population were obtained from the adjusted Poisson regression models.
†Expected counts were calculated by multiplying the predicted rates to the average disease prevalence (we used the Ontario disease-specific prevalence population presented in table 1).
‡Per cent change is calculated as compared to when AQHI=3.
AQHI, Air Quality Health Index; COPD, chronic obstructive pulmonary disease.